Press Releases :: Hancock Jaffe Laboratories, Inc. (HJLI)

Hancock Jaffe to Begin CoreoGraft First-in-Human Study

Oct 14, 2020

Hancock Jaffe Engages Syntactx for VenoValve U.S. Pivotal Trial

Oct 8, 2020

Hancock Jaffe Laboratories, Inc. Announces Pricing of $5.1 Million Registered Direct Offering Priced at the Market

Oct 7, 2020

Hancock Jaffe Announces Positive Nasdaq Listing Determination

Sep 21, 2020

Hancock Jaffe Enrolls Initial Patients for First-in-Human CoreoGraft Study

Aug 25, 2020

Hancock Jaffe Announces One Year Follow-up Data on Two Additional VenoValve Patients

Aug 21, 2020

Hancock Jaffe Regains Compliance with Nasdaq Stockholder's Equity Rule

Aug 10, 2020

Hancock Jaffe Receives Permission to Proceed with First-in-Human CoreoGraft Study

Jul 23, 2020

Hancock Jaffe Laboratories Announces Closings of $6.2 Million Offerings Including Full Exercise of Over-Allotment Option

Jul 21, 2020

Hancock Jaffe Laboratories Announces Pricing of $5.6 Million Offering

Jul 17, 2020

Show / Refresh / Reset / Delete

Views until show: 5
Seconds until show: 5